<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00622973</url>
  </required_header>
  <id_info>
    <org_study_id>SNF320000-113512/1</org_study_id>
    <secondary_id>KEK101_06</secondary_id>
    <secondary_id>SNF320000-113512/1</secondary_id>
    <secondary_id>SWISSMEDIC2007DR3215</secondary_id>
    <nct_id>NCT00622973</nct_id>
  </id_info>
  <brief_title>USPIO-enhanced and Diffusion-weighted MRI for the Detection of Pelvic Lymph Node Metastases</brief_title>
  <official_title>Noninvasive Detection of Clinically Occult Lymph Node Metastases in Prostate and Bladder Cancer Evaluated by USPIO-Enhanced MRI and Diffusion-Weighted MRI: A Histopathological Correlation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preoperative detection of lymph node metastases in patients with prostate or bladder cancer
      is crucial for selection of the appropriate treatment strategy (surgery, androgen deprivation
      with/or without radiation therapy or chemotherapy) and thus for patient prognosis. Until now
      CT or MRI have been the modalities of choice for preoperative staging procedures. However,
      current morphological assessment of lymph nodes based on size and shape is unable to detect
      smaller metastases or liable to give false positive results on lymph nodes with reactive
      hyperplasia. We hypothesize that USPIO-enhanced MRI combined with DW-MRI will be able to
      detect pelvic lymph node metastases preoperatively with high sensitivity and specificity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Discrimination of N positive (N+) vs. N negative (N0) patients (prostate and bladder cancer) using diffusion-weighted imaging, USPIO enhancement and both.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Preoperative localization of all suspected positive nodes in accordance to the predefined regions on both sides and in comparison with histopathology.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Node-by-node analysis of USPIO-enhanced and DW-MRI positive lymph nodes with histopathology.</measure>
    <time_frame>2-3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Diffusion-weighted MRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sinerem (USPIO)- enhanced MRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Imaging: diffusion-weighted MRI</intervention_name>
    <description>Diffusion-weighted MRI of the entire pelvis to detect lymph node metastases</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sinerem (USPIO) enhanced MRI</intervention_name>
    <description>USPIO (Sinerem) will be administered intravenously immediately after the first MR examination at a dose of 2.6 mg Fe/kg body weight diluted in 100 ml of saline (optimal dose according to: (9, 10)) during a period of about 30 minutes under medical supervision. Postcontrast MR imaging will be performed 24-36 hours after contrast medium injection.</description>
    <arm_group_label>B</arm_group_label>
    <other_name>SINEREM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically proven prostate cancer (T1-2N0M0 Gleason score 6-10)
             scheduled for radical prostatectomy or patients with histologically proven bladder
             cancer (T1-3bN0M0G3) scheduled for cystectomy

          -  Written informed consent to participate in this trial.

        Exclusion Criteria:

          -  Patients with contraindications for MRI (e.g. pacemaker, metal implants,
             claustrophobia).

          -  Patients in a critical cardiovascular state, with risk of decompensation after
             administration of the USPIO contrast agent.

          -  Patients with hemochromatosis or an allergy to dextran or iron compounds.

          -  Pregnant or breast-feeding women.

          -  Patients who have received gadolinium complexes within 2 days or iron oxide particles
             within 7 days before MRI.

          -  Patients who underwent chemotherapy or radiotherapy before surgery.

          -  Patients whose degree of cooperation is incompatible with carrying out the study.

          -  Patients with contraindications to Glucagon administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harriet C Thoeny, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Inselspital, Bern, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Thoeny HC, Triantafyllou M, Birkhaeuser FD, Froehlich JM, Tshering DW, Binser T, Fleischmann A, Vermathen P, Studer UE. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol. 2009 Apr;55(4):761-9. doi: 10.1016/j.eururo.2008.12.034. Epub 2009 Jan 7.</citation>
    <PMID>19144456</PMID>
  </results_reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2008</study_first_submitted>
  <study_first_submitted_qc>February 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2008</study_first_posted>
  <last_update_submitted>October 7, 2011</last_update_submitted>
  <last_update_submitted_qc>October 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Harriet C. Thoeny, MD</name_title>
    <organization>University Hospital Inselspital, Berne</organization>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>Bladder cancer</keyword>
  <keyword>Pelvic lymph node metastases</keyword>
  <keyword>Diffusion-weighted MRI</keyword>
  <keyword>Sinerem (USPIO)-enhanced MRI</keyword>
  <keyword>Imaging influence on surgery</keyword>
  <keyword>Noninvasive detection of pelvic lymph node metastases</keyword>
  <keyword>Influence of imaging protocol on surgical outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

